S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION

S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION

Bibliographic Details
Main Authors:	N. Jain, P. Thompson, J. Burger, A. Ferrajoli, K. Takahashi, Z. Estrov, G. Borthakur, P. Bose, T. Kadia, N. Pemmaraju, K. Sasaki, M. Konopleva, E. Jabbour, N. Garg, X. Wang, R. Kanagal-Shamanna, K. Patel, W. Wang, S. Wang, J. Jorgensen, W. Lopez, A. Ayala, W. Plunkett, V. Gandhi, H. Kantarjian, S. O’Brien, M. Keating, W. Wierda
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843488.43813.af

Similar Items

Celebrating 20 Years of IGHV Mutation Analysis in CLL
by: Nicholas Chiorazzi, et al.
Published: (2020-02-01)

P509: THE IMPACT OF THE NUMBER OF RAS MUTATIONS IN THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED FRONTLINE AT A SINGLE INSTITUTION.
by: Mahesh Swaminathan, et al.
Published: (2023-08-01)

The Emergence of Resistance Under Firstline INSTI Regimens
by: Xie Z, et al.
Published: (2022-08-01)

Spotlight on borderline-IGHV mutational status in chronic lymphocytic leukemia
by: Souraya Rammal, et al.
Published: (2024-06-01)

IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load
by: Dianna Hussmann, et al.
Published: (2021-06-01)

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV(mut) and IgHV(unmut) subgroups
by: Burns, A, et al.
Published: (2017)

P769: MUTATION PROFILES AND RISK STRATIFICATION IN HYPOCELLULAR MYELODYSPLASTIC SYNDROME
by: K. Kim, et al.
Published: (2022-06-01)

P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
by: S. Venugopal, et al.
Published: (2022-06-01)

P497: PROGNOSTIC IMPACT OF RAS AND C-KIT MUTATIONS (SINGLE VS. MULTIPLE) IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA TREATED WITH FLUDARABINE, CYTARABINE, G-CSF (FLAG) BASED REGIMEN
by: T. Abuasab, et al.
Published: (2022-06-01)

Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia
by: Ilaria Del Giudice, et al.
Published: (2019-02-01)

P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
by: Filippo Vit, et al.
Published: (2023-08-01)

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia
by: Matthew Kaufman, et al.
Published: (2022-07-01)

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia
by: Pietro Bulian, et al.
Published: (2017-11-01)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
by: Nyla A. Heerema, et al.
Published: (2020-05-01)

P754: INITIAL RESULTS OF PHASE I/II STUDY OF AZACITIDINE IN COMBINATION WITH QUIZARTINIB FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH FLT3 OR CBL MUTATION
by: T. Abuasab, et al.
Published: (2022-06-01)

IgE-associated IGHV genes from venom and peanut allergic individuals lack mutational evidence of antigen selection.
by: Yan Wang, et al.
Published: (2014-01-01)

P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)
by: T. Kadia, et al.
Published: (2022-06-01)

Clinical Laboratory Method for Detection of IGHV Mutation Status in Patients with CLL Validated by Igblast and IMGT/V-QUEST
by: Lasabova Z., et al.
Published: (2011-08-01)

Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes.
by: Nicola J Weston-Bell, et al.
Published: (2014-01-01)

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis.
by: María García-Álvarez, et al.
Published: (2017-01-01)

Correction: The periplasmic protein HslJ is the firstline of defense against oxidative stress in Acinetobacter baumannii
by: Daniela Scribano, et al.
Published: (2025-01-01)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
by: Samuel Urrutia, et al.
Published: (2023-08-01)

P611: NEXT-CLL: A NEW NGS-BASED METHOD FOR RAPID ASSESSMENT OF IGHV MUTATIONAL STATUS IN CHRONIC LYMPHOID LEUKEMIA
by: E. Bourbon, et al.
Published: (2022-06-01)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, C, et al.
Published: (2022)

IGHV Mutational Status in a Cohort of Bulgarian CLL Patients: High Unmutated CLL Prevalence in North-East Bulgaria
by: Yosifova A, et al.
Published: (2024-09-01)

Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption
by: Julio Delgado, et al.
Published: (2014-11-01)

UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
by: Sujata Bhoi, et al.
Published: (2016-02-01)

Oregon Project Firstline: A needs assessment of healthcare personnel infection prevention knowledge and training preferences
by: Nicholas Ida, et al.
Published: (2023-06-01)

S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY
by: M. Yilmaz, et al.
Published: (2022-06-01)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
by: Samuel Urrutia, et al.
Published: (2023-08-01)

IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study
by: Emelie Curovic Rotbain, et al.
Published: (2020-06-01)

Genetic Profiling in Chronic Lymphocytic Leukemia: The Role of TP53 Mutations and IGHV Status in Treatment Decision-Making – A Case Report
by: Kateryna Khurdepa, et al.
Published: (2024-10-01)

Association of Cytogenetics Aberrations and <i>IGHV</i> Mutations with Outcome in Chronic Lymphocytic Leukemia Patients in a Real-World Clinical Setting
by: Carolina Muñoz-Novas, et al.
Published: (2024-01-01)

Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group
by: Prajwal Boddu, et al.
Published: (2017-08-01)

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, CA, et al.
Published: (2022)

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies
by: Lachowiez, CA, et al.
Published: (2021)

P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS
by: J. Senapati, et al.
Published: (2022-06-01)

P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB
by: W. Macaron, et al.
Published: (2022-06-01)

P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: J. Senapati, et al.
Published: (2022-06-01)

P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE
by: K. Kim, et al.
Published: (2022-06-01)